Preskorn S - Search Results

1

How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study.

Shen J, Preskorn S, Dragalin V, Slomkowski M, Padmanabhan SK, Fardipour P, Sharma A, Krams M. Shen J, et al. Among authors: preskorn s. Innov Clin Neurosci. 2011 Jul;8(7):26-34. Innov Clin Neurosci. 2011. PMID: 21860843 Free PMC article.

2

Phase I trials: from traditional to newer approaches. Part I.

Macaluso M, Krams M, Preskorn SH. Macaluso M, et al. J Psychiatr Pract. 2011 May;17(3):200-3. doi: 10.1097/01.pra.0000398413.44244.f8. J Psychiatr Pract. 2011. PMID: 21586998

3

Phase I trials: from traditional to newer approaches part II.

Macaluso M, Krams M, Preskorn SH. Macaluso M, et al. J Psychiatr Pract. 2011 Jul;17(4):277-84. doi: 10.1097/01.pra.0000400265.37666.4e. J Psychiatr Pract. 2011. PMID: 21775829

4

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. Preskorn SH, et al. J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea. J Clin Psychopharmacol. 2008. PMID: 19011431 Clinical Trial.

5

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT. Lobello KW, et al. J Clin Psychiatry. 2010 Nov;71(11):1482-7. doi: 10.4088/JCP.08m04773blu. Epub 2010 Apr 6. J Clin Psychiatry. 2010. PMID: 20441720 Clinical Trial.

6

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.

Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Nichols AI, et al. Clin Drug Investig. 2011;31(3):155-67. doi: 10.2165/11586630-000000000-00000. Clin Drug Investig. 2011. PMID: 21288052 Clinical Trial.

7

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.

Macaluso M, Nichols AI, Preskorn SH. Macaluso M, et al. Prim Care Companion CNS Disord. 2015 Mar 19;17(2):10.4088/PCC.14r01710. doi: 10.4088/PCC.14r01710. eCollection 2015. Prim Care Companion CNS Disord. 2015. PMID: 26445693 Free PMC article.

8

How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction.

Macaluso M, Preskorn SH. Macaluso M, et al. J Psychiatr Pract. 2012 Mar;18(2):118-21. doi: 10.1097/01.pra.0000413277.11091.25. J Psychiatr Pract. 2012. PMID: 22418402 Review.

9

How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression.

Macaluso M, Drevets WC, Preskorn SH. Macaluso M, et al. J Psychiatr Pract. 2012 Jul;18(4):281-6. doi: 10.1097/01.pra.0000416018.83709.3e. J Psychiatr Pract. 2012. PMID: 22805902

10

Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing.

Macaluso M, Preskorn SH. Macaluso M, et al. J Psychiatr Pract. 2018 Nov;24(6):416-419. doi: 10.1097/PRA.0000000000000345. J Psychiatr Pract. 2018. PMID: 30395549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

358 results

Search Page

Filters